Skip to main content

Double antibody radioimmunoassay for monitoring metastatic breast cancer.

Publication ,  Journal Article
Schecter, RL; Major, PP; Kovac, PE; Ishida, M; Kovalik, EC; Dion, AS; Langleben, A; Boileau, G; Boos, G; Panasci, L
Published in: Br J Cancer
September 1988

We previously reported the production of a panel of murine monoclonal antibodies which recognize glycoproteins abnormally expressed in human breast tumours. Using two of these antibodies, a double antibody radioimmunoassay was designed to quantify levels of these breast tumour marker glycoproteins in serum. Marker levels greater than 28 units were considered abnormal. Using this criterion, 63% and 75% of patients with breast cancer stages I and II, respectively, and 88% of those with metastatic disease were found to have elevated marker levels. Thirteen percent of patients with non-malignant breast disease also had elevated marker levels. Elevated marker levels were also detected in patients with non breast neoplasms. One hundred and eleven women with metastatic disease were followed. Eighty-two percent of those with progressive disease and 73% of those where disease regressed had 20% changes in marker levels. These changes in marker levels preceded by up to 6 months changes in disease state. From these results we conclude that this assay may be useful for monitoring the course of disease in breast cancer patients.

Duke Scholars

Published In

Br J Cancer

DOI

ISSN

0007-0920

Publication Date

September 1988

Volume

58

Issue

3

Start / End Page

362 / 367

Location

England

Related Subject Headings

  • Radioimmunoassay
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Proteins
  • Neoplasm Metastasis
  • Humans
  • Glycoproteins
  • Female
  • Breast Neoplasms
  • Breast Diseases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schecter, R. L., Major, P. P., Kovac, P. E., Ishida, M., Kovalik, E. C., Dion, A. S., … Panasci, L. (1988). Double antibody radioimmunoassay for monitoring metastatic breast cancer. Br J Cancer, 58(3), 362–367. https://doi.org/10.1038/bjc.1988.220
Schecter, R. L., P. P. Major, P. E. Kovac, M. Ishida, E. C. Kovalik, A. S. Dion, A. Langleben, G. Boileau, G. Boos, and L. Panasci. “Double antibody radioimmunoassay for monitoring metastatic breast cancer.Br J Cancer 58, no. 3 (September 1988): 362–67. https://doi.org/10.1038/bjc.1988.220.
Schecter RL, Major PP, Kovac PE, Ishida M, Kovalik EC, Dion AS, et al. Double antibody radioimmunoassay for monitoring metastatic breast cancer. Br J Cancer. 1988 Sep;58(3):362–7.
Schecter, R. L., et al. “Double antibody radioimmunoassay for monitoring metastatic breast cancer.Br J Cancer, vol. 58, no. 3, Sept. 1988, pp. 362–67. Pubmed, doi:10.1038/bjc.1988.220.
Schecter RL, Major PP, Kovac PE, Ishida M, Kovalik EC, Dion AS, Langleben A, Boileau G, Boos G, Panasci L. Double antibody radioimmunoassay for monitoring metastatic breast cancer. Br J Cancer. 1988 Sep;58(3):362–367.

Published In

Br J Cancer

DOI

ISSN

0007-0920

Publication Date

September 1988

Volume

58

Issue

3

Start / End Page

362 / 367

Location

England

Related Subject Headings

  • Radioimmunoassay
  • Oncology & Carcinogenesis
  • Neoplasms
  • Neoplasm Proteins
  • Neoplasm Metastasis
  • Humans
  • Glycoproteins
  • Female
  • Breast Neoplasms
  • Breast Diseases